European Journal of Dermatology
MENUIs the high risk of anaphylaxis to omalizumab a contraindication to this treatment? Volume 29, numéro 1, January-February 2019
Tableaux
2 University of Lorraine,
EA 3450 DevAH,
Development, Adaptation, Cardio-Respiratory Regulations and Motor Control,
54000 Nancy, France
EA 3450 DevAH,
Development, Adaptation, Cardio-Respiratory Regulations and Motor Control,
54000 Nancy, France
5 Assistance Publique-Hôpitaux de Paris (AP-HP),
Armand-Trousseau Children Hospital,
Biochemistry Laboratory,
Allergy and Environment Team,
75000 Paris, France
Armand-Trousseau Children Hospital,
Biochemistry Laboratory,
Allergy and Environment Team,
75000 Paris, France
6 University of Lorraine,
54000 Nancy, France
54000 Nancy, France
- DOI : 10.1684/ejd.2018.3454
- Page(s) : 101-2
- Année de parution : 2019
Omalizumab is a recombinant humanized monoclonal antibody (mAb) targeting IgE, produced using Chinese hamster ovary (CHO) cell culture. It has been approved for the treatment of severe allergic asthma (SAA) and chronic urticaria but not for allergic rhinitis (AR), atopic dermatitis (AD) or food allergy, despite some benefits against these diseases [1]. Omalizumab treatment associated with allergen immunotherapy (AIT) can increase the tolerability of AIT [1]. Some anaphylactic reactions have been [...]